2023
Gallagher, S., Howard, S., McMahon, J., & Palmieri, C. (2023). Christmas cards: are senders full of joy and good cheer?. COGENT PSYCHOLOGY, 10(1). doi:10.1080/23311908.2022.2151727DOI: 10.1080/23311908.2022.2151727
Palmieri, C., Musson, A., Harper-Wynne, C., Wheatley, D., Bertelli, G., Macpherson, I. R., . . . Chowdhury, R. (2023). A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance & REG; Patient Program. BRITISH JOURNAL OF CANCER. doi:10.1038/s41416-023-02352-5DOI: 10.1038/s41416-023-02352-5
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib (vol 14, 4444, 2023) (Journal article)
Coombes, R. C., Howell, S., Lord, S. R., Kenny, L., Mansi, J., Mitri, Z., . . . Krebs, M. G. (2023). Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib (vol 14, 4444, 2023). NATURE COMMUNICATIONS, 14(1). doi:10.1038/s41467-023-40561-xDOI: 10.1038/s41467-023-40561-x
Coombes, R. C., Howell, S., Lord, S. R., Kenny, L., Mansi, J., Mitri, Z., . . . Krebs, M. G. (2023). Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. NATURE COMMUNICATIONS, 14(1). doi:10.1038/s41467-023-40061-yDOI: 10.1038/s41467-023-40061-y
Houten, R., Fleeman, N., Mahon, J., Chaplin, M., Edwards, K., Beale, S., . . . Palmieri, C. (2023). Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN. doi:10.1007/s41669-023-00405-2DOI: 10.1007/s41669-023-00405-2
Identification of targetable genomic profiling of breast cancer brain metastases identifies alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors (Preprint)
DOI: 10.21203/rs.3.rs-2484456/v1
2022
Giannoudis, A., Vareslija, D., Sharma, V., Zakaria, R., Platt-Higgins, A., Rudland, P. S., . . . Palmieri, C. (2022). Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression. ESMO OPEN, 7(6). doi:10.1016/j.esmoop.2022.100636DOI: 10.1016/j.esmoop.2022.100636
Palmieri, C., Owide, J., & Fryer, K. (2022). Estimated Prevalence of Metastatic Breast Cancer in England, 2016-2021.. JAMA network open, 5(12), e2248069. doi:10.1001/jamanetworkopen.2022.48069DOI: 10.1001/jamanetworkopen.2022.48069
Siggins, M. K., Davies, K., Fellows, R., Thwaites, R. S., Baillie, J. K., Semple, M. G., . . . ISARIC4C Investigators. (2022). Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.. Immunology. doi:10.1111/imm.13585DOI: 10.1111/imm.13585
Wysocki, O., Zhou, C., Rogado, J., Huddar, P., Shotton, R., Tivey, A., . . . Co-Care, E. S. M. O. (2022). An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves. Cancers, 14(16). doi:10.3390/cancers14163931DOI: 10.3390/cancers14163931
UK survey measuring informational needs & QoL in women living with metastatic breast cancer (LIMBER) (Conference Paper)
Jenkins, V. A., Russ, S., Starkings, R., Tait, A., Stephen, L., May, S., . . . FallowField, L. J. (2022). UK survey measuring informational needs & QoL in women living with metastatic breast cancer (LIMBER). In ANNALS OF ONCOLOGY Vol. 33 (pp. S637). doi:10.1016/j.annonc.2022.07.258DOI: 10.1016/j.annonc.2022.07.258
Ortega-Martorell, S., Riley, P., Olier, I., Raidou, R. G., Casana-Eslava, R., Rea, M., . . . Palmieri, C. (2022). Breast cancer patient characterisation and visualisation using deep learning and fisher information networks. SCIENTIFIC REPORTS, 12(1). doi:10.1038/s41598-022-17894-6DOI: 10.1038/s41598-022-17894-6
Fatayer, H., O'Connell, R. L., Bannon, F., Coles, C. E., Copson, E., Cutress, R. I., . . . McIntosh, S. A. (2022). Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study. BRITISH JOURNAL OF SURGERY, 109(9), 800-803. doi:10.1093/bjs/znac131DOI: 10.1093/bjs/znac131
Winter, M., Coleman, R., Kendall, J., Palmieri, C., Twelves, C., Howell, S., . . . Brown, J. (2022). A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo((TM))) in breast cancer patients with BONe metastases: CARBON trial results. JOURNAL OF BONE ONCOLOGY, 35. doi:10.1016/j.jbo.2022.100442DOI: 10.1016/j.jbo.2022.100442
Hall, B. J., Bhojwani, A. A., Wong, H., Law, A., Flint, H., Ahmed, E., . . . Palmieri, C. (2022). Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience. BREAST JOURNAL, 2022. doi:10.1155/2022/7146172DOI: 10.1155/2022/7146172
Razis, E., Escudero, M. J., Palmieri, C., Mueller, V., Bartsch, R., Rossi, G., . . . Linderholm, B. (2022). Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force. ESMO OPEN, 7(3). doi:10.1016/j.esmoop.2022.100483DOI: 10.1016/j.esmoop.2022.100483
Bhogal, T., Cameron, D., & Palmieri, C. (2022). Central nervous system disease in phase III studies for advanced HER2 positive breast cancer: A review. BREAST, 63, 85-100. doi:10.1016/j.breast.2022.03.013DOI: 10.1016/j.breast.2022.03.013
Lee, R. J., Wysocki, O., Zhou, C., Shotton, R., Tivey, A., Lever, L., . . . Armstrong, A. C. (2022). Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital.. JCO clinical cancer informatics, 6, e2100177. doi:10.1200/cci.21.00177DOI: 10.1200/cci.21.00177
Rivaroxaban compared to no treatment in early breast cancer patients (the TIP Trial): initial findings for a phase II preoperative window-of-opportunity randomised controlled trial (Conference Paper)
Kirwan, C. C., Castle, J., Pritchard, S. A., Bundred, N. J., Thachill, J., Harvey, J. R., . . . Holcombe, C. (2022). Rivaroxaban compared to no treatment in early breast cancer patients (the TIP Trial): initial findings for a phase II preoperative window-of-opportunity randomised controlled trial. In THROMBOSIS RESEARCH Vol. 213 (pp. S5-S6). Retrieved from https://www.webofscience.com/
Khoury, E., Nevitt, S., Madsen, W. R., Turtle, L., Davies, G., & Palmieri, C. (2022). Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer A Systematic Review and Meta-analysis. JAMA NETWORK OPEN, 5(5). doi:10.1001/jamanetworkopen.2022.10880DOI: 10.1001/jamanetworkopen.2022.10880
The importance of ARG2 expression in the immune-depleted microenvironment of primary breast cancer and brain metastasis (Conference Paper)
Giannoudis, A., Vareslija, D., Sharma, V., Zakaria, R., Platt-Higgins, A., Rudland, P., . . . Palmieri, C. (2022). The importance of ARG2 expression in the immune-depleted microenvironment of primary breast cancer and brain metastasis. In ANNALS OF ONCOLOGY Vol. 33 (pp. S132). doi:10.1016/j.annonc.2022.03.035DOI: 10.1016/j.annonc.2022.03.035
Comprehensive analysis of the gene rearrangements within 822 breast cancer brain metastases reveals an enrichment of cyclin dependent kinase 12 rearrangements in HER2-positive brain metastases (Conference Paper)
Bhogal, T., Sokol, E., Ramkissoon, S., Giannoudis, A., McGregor, K., Clark, A., . . . Palmieri, C. (2022). Comprehensive analysis of the gene rearrangements within 822 breast cancer brain metastases reveals an enrichment of cyclin dependent kinase 12 rearrangements in HER2-positive brain metastases. In CANCER RESEARCH Vol. 82. doi:10.1158/1538-7445.SABCS21-P5-07-04DOI: 10.1158/1538-7445.SABCS21-P5-07-04
Comprehensive assessment of the genomic landscape of breast cancer brain metastases reveals targetable alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors (Conference Paper)
Giannoudis, A., Sokol, E., Ramkissoon, S. H., Bhogal, T., McGregor, K., Clark, A., . . . Palmieri, C. (2022). Comprehensive assessment of the genomic landscape of breast cancer brain metastases reveals targetable alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors. In CANCER RESEARCH Vol. 82. doi:10.1158/1538-7445.SABCS21-PD4-09DOI: 10.1158/1538-7445.SABCS21-PD4-09
Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., . . . Screaton, G. R. (2022). SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.. Cell, 185(3), 467-484.e15. doi:10.1016/j.cell.2021.12.046DOI: 10.1016/j.cell.2021.12.046
Expert Discussion: SABCS 2021 (Journal article)
Bartsch, R., Kolberg-Liedtke, C., Jerusalem, G., Palmieri, C., & Janni, W. (2022). Expert Discussion: SABCS 2021. BREAST CARE, 17(1), 101-106. doi:10.1159/000521762DOI: 10.1159/000521762
2021
Giannoudis, A., Sartori, A., Eastoe, L., Zakaria, R., Charlton, C., Hickson, N., . . . Palmieri, C. (2021). Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival. BREAST CANCER RESEARCH AND TREATMENT, 190(2), 241-253. doi:10.1007/s10549-021-06364-8DOI: 10.1007/s10549-021-06364-8
Wickenhagen, A., Sugrue, E., Lytras, S., Kuchi, S., Noerenberg, M., Turnbull, M. L., . . . Wilson, S. J. (2021). A prenylated dsRNA sensor protects against severe COVID-19. SCIENCE, 374(6567). doi:10.1126/science.abj3624DOI: 10.1126/science.abj3624
Zakaria, R., Radon, M., Mills, S., Mitchell, D., Palmieri, C., Chung, C., & Jenkinson, M. D. (2021). The Role of the Immune Response in Brain Metastases: Novel Imaging Biomarkers for Immunotherapy. FRONTIERS IN ONCOLOGY, 11. doi:10.3389/fonc.2021.711405DOI: 10.3389/fonc.2021.711405
Huang, R. S. P., Haberberger, J., McGregor, K., Mata, D. A., Decker, B., Hiemenz, M. C., . . . Ramkissoon, S. H. (2021). Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. ONCOLOGIST, 26(10), 835-844. doi:10.1002/onco.13855DOI: 10.1002/onco.13855
A global survey of the management of carcinomatous meningitis (CM) in breast cancer patients (Conference Paper)
Razis, E., Thulin, A. G., Bartsch, R., Escudero, M. J., Linderholm, B., Fumagali, D., . . . Witzel, I. (2021). A global survey of the management of carcinomatous meningitis (CM) in breast cancer patients. In ANNALS OF ONCOLOGY Vol. 32 (pp. S500). doi:10.1016/j.annonc.2021.08.594DOI: 10.1016/j.annonc.2021.08.594
A real-world data analysis: The first United Kingdom experience of cyclin-dependent kinase 4/6 inhibitor in advanced breast cancer in the National Health Service within an access program (Conference Paper)
Palmieri, C., Musson, A., Harper-Wynne, C., Wheatley, D., Bertelli, G., MacPherson, I., . . . Chowdhury, R. (2021). A real-world data analysis: The first United Kingdom experience of cyclin-dependent kinase 4/6 inhibitor in advanced breast cancer in the National Health Service within an access program. In ANNALS OF ONCOLOGY Vol. 32 (pp. S464). doi:10.1016/j.annonc.2021.08.523DOI: 10.1016/j.annonc.2021.08.523
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer The REACT Randomized Clinical Trial (Journal article)
Coombes, R. C., Tovey, H., Kilburn, L., Mansi, J., Palmieri, C., Bartlett, J., . . . Bliss, J. M. (2021). Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer The REACT Randomized Clinical Trial. JAMA ONCOLOGY, 7(9), 1291-1301. doi:10.1001/jamaoncol.2021.2193DOI: 10.1001/jamaoncol.2021.2193
Palmieri, C., Turtle, L., Drake, T., Harrison, E., Docherty, A., Greenhalf, B., . . . Semple, M. M. G. (2021). LBA60 Prospective data of >20,000 hospitalised patients with cancer and COVID-19 derived from the International Severe Acute Respiratory and emerging Infections Consortium WHO Coronavirus Clinical Characterisation Consortium: CCP-CANCER UK. In Annals of oncology : official journal of the European Society for Medical Oncology Vol. 32 (pp. S1337).
Prospective data of > 20,000 hospitalised patients with cancer and COVID-19 derived from the International Severe Acute Respiratory and emerging Infections Consortium WHO Coronavirus Clinical Characterisation Consortium: CCP-CANCER UK (Conference Paper)
Palmieri, C., Turtle, L., Drake, T., Harrison, E., Docherty, A., Greenhalf, B., . . . Semple, M. M. G. (2021). Prospective data of > 20,000 hospitalised patients with cancer and COVID-19 derived from the International Severe Acute Respiratory and emerging Infections Consortium WHO Coronavirus Clinical Characterisation Consortium: CCP-CANCER UK. In ANNALS OF ONCOLOGY Vol. 32 (pp. S1337). doi:10.1016/j.annonc.2021.08.2141DOI: 10.1016/j.annonc.2021.08.2141
Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR plus BC) (Conference Paper)
Howell, S. J., Krebs, M. G., Lord, S., Kenny, L., Bahl, A., Clack, G., . . . Coombes, R. C. (2021). Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR plus BC). In ANNALS OF ONCOLOGY Vol. 32 (pp. S477-S478). doi:10.1016/j.annonc.2021.08.548DOI: 10.1016/j.annonc.2021.08.548
Drake, T. M., Riad, A. M., Fairfield, C. J., Egan, C., Knight, S. R., Pius, R., . . . Semple, M. G. (2021). Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. LANCET, 398(10296), 223-237. Retrieved from https://www.webofscience.com/
Palmieri, C., & Macpherson, I. R. (2021). A review of the evidence base for utilizing Child-Pugh criteria for guiding dosing of anticancer drugs in patients wan cancer and liver impairment. ESMO OPEN, 6(3). doi:10.1016/j.esmoop.2021.100162DOI: 10.1016/j.esmoop.2021.100162
Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR plus /ER plus breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study (Conference Paper)
Palmieri, C., Linden, H., Birrell, S., Lim, E., Schwartzberg, L. S., Rugo, H. S., . . . Overmoyer, B. (2021). Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR plus /ER plus breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study. In ANNALS OF ONCOLOGY Vol. 32 (pp. S66). doi:10.1016/j.annonc.2021.03.114DOI: 10.1016/j.annonc.2021.03.114
Genomic Profiling Using The UltraSEEK Panel Identifies Discordancy Between Paired Primary And Breast Cancer Brain Metastases And An Association With Brain Metastasis-Free Survival (Preprint)
DOI: 10.21203/rs.3.rs-377753/v1
Lee, R. J., Wysocki, O., Bhogal, T., Shotton, R., Tivey, A., Angelakas, A., . . . Armstrong, A. C. (2021). Erratum to "Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome". ESMO OPEN, 6(2). doi:10.1016/j.esmoop.2021.100056DOI: 10.1016/j.esmoop.2021.100056
Macpherson, I. R., He, Y., & Palmieri, C. (2021). Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305. BREAST CANCER RESEARCH, 23(1). doi:10.1186/s13058-021-01407-wDOI: 10.1186/s13058-021-01407-w
Sigfrid, L., Cevik, M., Jesudason, E., Lim, W. S., Rello, J., Amuasi, J., . . . Scott, J. T. (2021). What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol.. BMJ Open, 11(3), e043887. doi:10.1136/bmjopen-2020-043887DOI: 10.1136/bmjopen-2020-043887
Vrdoljak, E., Gligorov, J., Wierinck, L., Conte, P., De Greve, J., Meunier, F., . . . Cardoso, F. (2021). Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe. BREAST, 55, 79-90. doi:10.1016/j.breast.2020.12.005DOI: 10.1016/j.breast.2020.12.005
Lee, R. J., Wysocki, O., Bhogal, T., Shotton, R., Tivey, A., Angelakas, A., . . . Armstrong, A. C. (2021). Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome. ESMO OPEN, 6(1). doi:10.1016/j.esmoop.2020.100005DOI: 10.1016/j.esmoop.2020.100005
Hickey, T. E., Selth, L. A., Chia, K. M., Laven-Law, G., Milioli, H. H., Roden, D., . . . Tilley, W. D. (2021). The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. NATURE MEDICINE, 27(2), 310-+. doi:10.1038/s41591-020-01168-7DOI: 10.1038/s41591-020-01168-7
Bhogal, T., Khan, U. T., Lee, R., Stockdale, A., Hesford, C., Potti-Dhananjaya, V., . . . Palmieri, C. (2021). Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.. Leukemia & lymphoma, 1-16. doi:10.1080/10428194.2021.1876865DOI: 10.1080/10428194.2021.1876865
Whitehead, I., Irwin, G. W., Bannon, F., Coles, C. E., Copson, E., Cutress, R. I., . . . McIntosh, S. A. (2021). The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making. BMC CANCER, 21(1). doi:10.1186/s12885-020-07757-6DOI: 10.1186/s12885-020-07757-6
1'-Acetoxychavicol Acetate from Alpinia galanga Represses Proliferation and Invasion, and Induces Apoptosis via HER2-signaling in Endocrine-Resistant Breast Cancer Cells. (Journal article)
Pradubyat, N., Giannoudis, A., Elmetwali, T., Mahalapbutr, P., Palmieri, C., Mitrpant, C., & Ketchart, W. (2021). 1'-Acetoxychavicol Acetate from Alpinia galanga Represses Proliferation and Invasion, and Induces Apoptosis via HER2-signaling in Endocrine-Resistant Breast Cancer Cells.. Planta Medica. doi:10.1055/a-1307-3997DOI: 10.1055/a-1307-3997
A NATIONAL STUDY OF THE EXPERIENCES, INFORMATION NEEDS AND ATTITUDES TO CLINICAL RESEARCH OF PATIENTS LIVING WITH SECONDARY BREAST CANCER IN THE UK (Conference Paper)
Stephen, L., Dunn, J., Palmieri, C., & Balmer, C. (2021). A NATIONAL STUDY OF THE EXPERIENCES, INFORMATION NEEDS AND ATTITUDES TO CLINICAL RESEARCH OF PATIENTS LIVING WITH SECONDARY BREAST CANCER IN THE UK. In BREAST Vol. 59 (pp. S42-S43). Retrieved from https://www.webofscience.com/
A randomised phase IB/IIA study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases (CARBON) - Safety and preliminary efficacy findings (Conference Paper)
Winter, M., Kendall, J., Brown, S., Rathbone, E., Wilson, C., Howell, S., . . . Brown, J. (2021). A randomised phase IB/IIA study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases (CARBON) - Safety and preliminary efficacy findings. In CANCER RESEARCH Vol. 81. Retrieved from https://www.webofscience.com/
BMSCOPE: A SYSTEMATIC MAPPING REVIEW OF BRAIN/LEPTOMENINGEAL METASTASIS CLINICAL STUDIES FROM 2010 TO 2020 (Conference Paper)
Cheng, V. W. T., Heywood, R., Zakaria, R., Burger, R., Fitzpatrick, A., Zucker, K., . . . Jenkinson, M. D. (2021). BMSCOPE: A SYSTEMATIC MAPPING REVIEW OF BRAIN/LEPTOMENINGEAL METASTASIS CLINICAL STUDIES FROM 2010 TO 2020. In NEURO-ONCOLOGY Vol. 23 (pp. 51). Retrieved from https://www.webofscience.com/
Page, K., Martinson, L. J., Fernandez-Garcia, D., Hills, A., Gleason, K. L. T., Gray, M. C., . . . Shaw, J. A. (2021). Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. JCO PRECISION ONCOLOGY, 5, 1768-1776. doi:10.1200/PO.20.00522DOI: 10.1200/PO.20.00522
Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER plus /AR plus breast cancer - final results from an international Phase 2 randomized study (Conference Paper)
Palmieri, C., Linden, H., Birrell, S., Lim, E., Schwartzberg, L. S., Rugo, H. S., . . . Overmoyer, B. (2021). Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER plus /AR plus breast cancer - final results from an international Phase 2 randomized study. In CANCER RESEARCH Vol. 81. Retrieved from https://www.webofscience.com/
Morgan, A. J., Giannoudis, A., & Palmieri, C. (2021). The genomic landscape of breast cancer brain metastases: a systematic review.. The Lancet. Oncology, 22(1), e7-e17. doi:10.1016/S1470-2045(20)30556-8DOI: 10.1016/S1470-2045(20)30556-8
2020
Lee, R. J., Zhou, C., Wysocki, O., Shotton, R., Tivey, A., Lever, L., . . . Armstrong, A. C. (2020). Establishment of CORONET; COVID-19 Risk in Oncology Evaluation Tool to identify cancer patients at low versus high risk of severe complications of COVID-19 infection upon presentation to hospital. doi:10.1101/2020.11.30.20239095DOI: 10.1101/2020.11.30.20239095
Giannoudis, A., Malki, M. I., Rudraraju, B., Mohhamed, H., Menon, S., Liloglou, T., . . . Palmieri, C. (2020). Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer. Breast Cancer Research, 22(1). doi:10.1186/s13058-020-01359-7DOI: 10.1186/s13058-020-01359-7
Trastuzumab Beyond Progression in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: UK Practice now and in the Future (Journal article)
Robinson, T., Palmieri, C., & Braybrooke, J. P. (2020). Trastuzumab Beyond Progression in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: UK Practice now and in the Future. CLINICAL ONCOLOGY, 32(10), 636-638. doi:10.1016/j.clon.2020.04.008DOI: 10.1016/j.clon.2020.04.008
Palmieri, C., Turtle, L., Docherty, A., Harrison, E., Drake, T., Greenhalf, B., . . . Semple, M. G. (2020). Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international Severe Acute Respiratory and emerging Infections Consortium, WHO Coronavirus Clinical Characterisation Consortium. In ANNALS OF ONCOLOGY Vol. 31 (pp. S992). doi:10.1016/j.annonc.2020.08.1735DOI: 10.1016/j.annonc.2020.08.1735
Sigfrid, L., Cevik, M., Jesudason, E., Lim, W. S., Rello, J., Amuasi, J. H., . . . Scott, J. (2020). What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? - A harmonised, global longitudinal observational study. doi:10.1101/2020.08.26.20180950DOI: 10.1101/2020.08.26.20180950
Castle, J., Blower, E., Bundred, N. J., Harvey, J. R., Thachil, J., Marshall, A., . . . Kirwan, C. C. (2020). Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial. TRIALS, 21(1). doi:10.1186/s13063-020-04675-7DOI: 10.1186/s13063-020-04675-7
Palmieri, C., Palmer, D., Openshaw, P. J., Baille, J. K., Semple, M. G., & Turtle, L. (2020). Cancer datasets and the SARS-CoV-2 pandemic: establishing principles for collaboration.. ESMO Open, 5(3). doi:10.1136/esmoopen-2020-000825DOI: 10.1136/esmoopen-2020-000825
A breast cancer trainees research collaborative group prospective study of treatment and outcomes related to central nervous system disease secondary to breast cancer in the United Kingdom (Conference Paper)
Cheng, V. W. T., McKenzie, H. S., Kwan, A., Konstantis, A., Ma, R., Teo, P. J., . . . Palmieri, C. (2020). A breast cancer trainees research collaborative group prospective study of treatment and outcomes related to central nervous system disease secondary to breast cancer in the United Kingdom. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.SABCS19-OT3-10-02DOI: 10.1158/1538-7445.SABCS19-OT3-10-02
A systematic review of the receptor status and genomic landscape of breast cancer brain metastases (Conference Paper)
Morgan, A. J., Giannoudis, A., & Palmieri, C. (2020). A systematic review of the receptor status and genomic landscape of breast cancer brain metastases. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.SABCS19-P4-05-22DOI: 10.1158/1538-7445.SABCS19-P4-05-22
National utilisation of neoadjuvant systemic therapy and impact on surgical treatment - A prospective multi-centre cohort study (Conference Paper)
McIntosh, S. A., Irwin, G. W., Bannon, F., Coles, C., Copson, E., Cutress, R., . . . Potter, S. (2020). National utilisation of neoadjuvant systemic therapy and impact on surgical treatment - A prospective multi-centre cohort study. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.SABCS19-P2-16-04DOI: 10.1158/1538-7445.SABCS19-P2-16-04
The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer (Conference Paper)
Lim, E., Hickey, T. A., Selth, L. A., Chia, K. M., Milioli, H. H., Roden, D., . . . Tilley, W. D. (2020). The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.SABCS19-GS2-03DOI: 10.1158/1538-7445.SABCS19-GS2-03
Giannoudis, A., Malki, M. I., Mohammed, H., Rudraraju, B., Menon, S., Ali, S., . . . Palmieri, C. (2020). The regulatory role of activating transcription factor-2 (ATF2) in modulating tamoxifen resistance in estrogen-receptor positive breast cancer. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.SABCS19-P6-04-18DOI: 10.1158/1538-7445.SABCS19-P6-04-18
UltraSEEK breast cancer panel for low frequency mutation detection in breast cancer brain metastasis (Conference Paper)
Giannoudis, A., Eastoe, L., Charlton, C., Hickson, N., Zakaria, R., Platt-Higgins, A., . . . Palmieri, C. (2020). UltraSEEK breast cancer panel for low frequency mutation detection in breast cancer brain metastasis. In CANCER RESEARCH Vol. 80. doi:10.1158/1538-7445.SABCS19-P4-09-07DOI: 10.1158/1538-7445.SABCS19-P4-09-07
Coleman, R., Brown, J., Rathbone, E., Flanagan, L., Reid, A., Kendall, J., . . . Brown, S. (2020). CApecitabine plus Radium-223 (Xofigo (TM)) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial. TRIALS, 21(1). doi:10.1186/s13063-019-3643-6DOI: 10.1186/s13063-019-3643-6
Surgical outcomes following neoadjuvant chemotherapy: a UK national prospective multi-centre cohort study (Conference Paper)
McIntosh, S. A., Bannon, F., Coles, C. E., Copson, E., Cutress, R. I., Dave, R. V., . . . Potter, S. (2020). Surgical outcomes following neoadjuvant chemotherapy: a UK national prospective multi-centre cohort study. In BREAST CANCER RESEARCH AND TREATMENT Vol. 180 (pp. 528-529). Retrieved from https://www.webofscience.com/
The Breast Cancer Trainees Research Collaborative Group: A New Multidisciplinary Network to Facilitate Breast Cancer Research (Journal article)
Cheng, V. W. T., Heetun, A., Robinson, T., Coles, C. E., Palmieri, C., Rea, D., & Copson, E. R. (2020). The Breast Cancer Trainees Research Collaborative Group: A New Multidisciplinary Network to Facilitate Breast Cancer Research. CLINICAL ONCOLOGY, 32(1), E16-E18. doi:10.1016/j.clon.2019.06.019DOI: 10.1016/j.clon.2019.06.019
The breast cancer trainees research collaborative group (Conference Paper)
Copson, E., Coles, C., Kirwan, C., McIntosh, S., Palmieri, C., & Rea, D. (2020). The breast cancer trainees research collaborative group. In BREAST CANCER RESEARCH AND TREATMENT Vol. 180 (pp. 595). Retrieved from https://www.webofscience.com/
The landscape of systemic regimens used routinely in the neoadjuvant setting in the UK: the NEST national prospective multi-centre cohort study (Conference Paper)
Copson, E. R., Bannon, F., Coles, C. E., Cutress, R. I., Dave, R. V., Gardiner, M., . . . McIntosh, S. A. (2020). The landscape of systemic regimens used routinely in the neoadjuvant setting in the UK: the NEST national prospective multi-centre cohort study. In BREAST CANCER RESEARCH AND TREATMENT Vol. 180 (pp. 561-562). Retrieved from https://www.webofscience.com/
Window of opportunity treatment in breast cancer (Journal article)
Chen, J., Easwaralingam, N., Warrier, S., Ong, A., Carson, E. -K., Mak, C., . . . Segara, D. (2020). Window of opportunity treatment in breast cancer. ANZ JOURNAL OF SURGERY, 90(1-2), 34-40. doi:10.1111/ans.15487DOI: 10.1111/ans.15487
2019
Giannoudis, A., Clarke, K., Zakaria, R., Vareslija, D., Farahani, M., Rainbow, L., . . . Palmieri, C. (2019). A novel panel of differentially-expressed microRNAs in breast cancer brain metastasis may predict patient survival. SCIENTIFIC REPORTS, 9. doi:10.1038/s41598-019-55084-zDOI: 10.1038/s41598-019-55084-z
Prospective Observational Study in Patients with Metastatic Breast Cancer Involving the Central Nervous System (PRIMROSE) (Conference Paper)
Fitzpatrick, A., Konstantis, A., & Palmieri, C. (2019). Prospective Observational Study in Patients with Metastatic Breast Cancer Involving the Central Nervous System (PRIMROSE). In CLINICAL ONCOLOGY Vol. 31 (pp. E108). doi:10.1016/j.clon.2019.03.016DOI: 10.1016/j.clon.2019.03.016
Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution (Journal article)
Palmieri, C., & Macpherson, I. (2019). Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution. LANCET ONCOLOGY, 20(6), E289. doi:10.1016/S1470-2045(19)30296-7DOI: 10.1016/S1470-2045(19)30296-7
Ruenraroengsak, P., Kiryushko, D., Theodorou, I. G., Klosowski, M. M., Taylor, E. R., Niriella, T., . . . Porter, A. E. (2019). Frizzled-7-targeted delivery of zinc oxide nanoparticles to drug-resistant breast cancer cells. NANOSCALE, 11(27), 12858-12870. doi:10.1039/c9nr01277jDOI: 10.1039/c9nr01277j
Real-world data regarding the efficacy of neoadjuvant carboplatin-paclitaxel followed by dose-dense adriamycin-cyclophosphamide for triple-negative early breast cancer. (Conference Paper)
Bhojwani, A. A., Flint, H., Hall, B. J., Wong, H., Innes, H., Cliff, J., . . . Palmieri, C. (2019). Real-world data regarding the efficacy of neoadjuvant carboplatin-paclitaxel followed by dose-dense adriamycin-cyclophosphamide for triple-negative early breast cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37. doi:10.1200/JCO.2019.37.15_suppl.e12559DOI: 10.1200/JCO.2019.37.15_suppl.e12559
Real-world evidence regarding the efficacy and toxicity of neoadjuvant trastuzumab and pertuzumab in the management of HER2-positive early-breast cancer. (Conference Paper)
Hall, B. J., Bhojwani, A. A., Innes, H., Ahmed, E., Cliff, J., Malik, Z., . . . Palmieri, C. (2019). Real-world evidence regarding the efficacy and toxicity of neoadjuvant trastuzumab and pertuzumab in the management of HER2-positive early-breast cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37. doi:10.1200/JCO.2019.37.15_suppl.e12108DOI: 10.1200/JCO.2019.37.15_suppl.e12108
Szijgyarto, Z., Flach, K. D., Opdam, M., Palmieri, C., Linn, S. C., Wesseling, J., . . . Coombes, R. C. (2019). Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES. BREAST CANCER RESEARCH AND TREATMENT, 175(1), 149-163. doi:10.1007/s10549-018-05110-xDOI: 10.1007/s10549-018-05110-x
Olsson-Brown, A., Piskilidis, P., O'Hagan, J., Thorp, N., Robson, P., Innes, H., . . . Palmieri, C. (2019). The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool. BREAST, 44, 94-100. doi:10.1016/j.breast.2019.01.005DOI: 10.1016/j.breast.2019.01.005
Identification of microRNAs differentially expressed in brain metastasis secondary to breast cancer (Conference Paper)
Giannoudis, A., Clarke, K., Zakaria, R., Vareslija, D., Farahani, M., Rainbow, L., . . . Palmieri, C. (2019). Identification of microRNAs differentially expressed in brain metastasis secondary to breast cancer. In CANCER RESEARCH Vol. 79. doi:10.1158/1538-7445.SABCS18-P6-05-02DOI: 10.1158/1538-7445.SABCS18-P6-05-02
Profiling the early haematological dynamics and treatment modifications with palbociclib when used as first line treatment for ER-positive, HER2-negative metastatic breast cancer (Conference Paper)
Bhojwani, A., Flint, H., Hall, B., Wong, H., Innes, H., Cliff, J., . . . Palmieri, C. (2019). Profiling the early haematological dynamics and treatment modifications with palbociclib when used as first line treatment for ER-positive, HER2-negative metastatic breast cancer. In CANCER RESEARCH Vol. 79. doi:10.1158/1538-7445.SABCS18-P6-18-32DOI: 10.1158/1538-7445.SABCS18-P6-18-32
Real world experience of the medical and surgical management of HER2 positive early breast cancer treated with neoadjuvant trastuzumab and pertuzumab via the NHS England cancer drug fund (Conference Paper)
Hall, B., Bhojwani, A., Innes, H., Ahmed, E., Cliff, J., Malik, Z., . . . Palmieri, C. (2019). Real world experience of the medical and surgical management of HER2 positive early breast cancer treated with neoadjuvant trastuzumab and pertuzumab via the NHS England cancer drug fund. In CANCER RESEARCH Vol. 79. doi:10.1158/1538-7445.SABCS18-P6-17-27DOI: 10.1158/1538-7445.SABCS18-P6-17-27
Radiant-BC Platform Trial: Development of an efficient multiarm multi-stage early phase trial of radiosurgery with immunotherapy and systemic therapies in breast cancer patients with brain metastases using a flexible Bayesian framework (Conference Paper)
Yap, C., Kong, A., Slade, D., Jackson, R., Savage, J., Sanghera, P., . . . Palmieri, C. (2019). Radiant-BC Platform Trial: Development of an efficient multiarm multi-stage early phase trial of radiosurgery with immunotherapy and systemic therapies in breast cancer patients with brain metastases using a flexible Bayesian framework. In TRIALS Vol. 20. Retrieved from https://www.webofscience.com/
Irwin, G. W., Bannon, F., Coles, C. E., Copson, E., Cutress, R. I., Dave, R. V., . . . McIntosh, S. A. (2019). The NeST (neoadjuvant systemic therapy in breast cancer) study - Protocol for a prospective multi-centre cohort study to assess the current utilization and short-term outcomes of neoadjuvant systemic therapies in breast cancer. INTERNATIONAL JOURNAL OF SURGERY PROTOCOLS, 18, 5-11. doi:10.1016/j.isjp.2019.10.002DOI: 10.1016/j.isjp.2019.10.002
2018
Patten, D. K., Corleone, G., Gyorffy, B., Perone, Y., Slaven, N., Barozzi, I., . . . Magnani, L. (2018). Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. NATURE MEDICINE, 24(9), 1469-+. doi:10.1038/s41591-018-0091-xDOI: 10.1038/s41591-018-0091-x
Ricciardelli, C., Bianco-Miotto, T., Jindal, S., Butler, L. M., Leung, S., McNeil, C. M., . . . Tilley, W. D. (2018). The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. Clinical Cancer Research, 24(10), 2328-2341. doi:10.1158/1078-0432.CCR-17-1199DOI: 10.1158/1078-0432.CCR-17-1199
Cheang, M. C. U., Bliss, J. M., Viale, G., Speirs, V., Palmieri, C., Shaaban, A., . . . Coombes, R. C. (2018). Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES. BREAST CANCER RESEARCH AND TREATMENT, 168(1), 169-178. doi:10.1007/s10549-017-4543-7DOI: 10.1007/s10549-017-4543-7
A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT - Randomised EuropeAn celecoxib trial) (Conference Paper)
Coombes, R. C., Tovey, H., Kilburn, L., Mansi, J., Palmieri, C., Bartlett, J., . . . Bliss, J. (2018). A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT - Randomised EuropeAn celecoxib trial). In CANCER RESEARCH Vol. 78. Retrieved from https://www.webofscience.com/
A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA) (Conference Paper)
Loibl, S., Barinoff, J., Seiler, S., Decker, T., Denkert, C., Hardy-Bessard, A. -C., . . . Thill, M. (2018). A randomized, open-label, multi-center phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment strategy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer in a real world setting (PADMA). In CANCER RESEARCH Vol. 78. Retrieved from https://www.webofscience.com/
IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients (vol 165, pg 343, 2017) (Journal article)
Palmieri, C., Stein, R. C., Liu, X., Hudson, E., Nicholas, H., Sasano, H., . . . Coombes, R. C. (2018). IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients (vol 165, pg 343, 2017). BREAST CANCER RESEARCH AND TREATMENT, 167(1), 407. doi:10.1007/s10549-017-4539-3DOI: 10.1007/s10549-017-4539-3
2017
Palmieri, C., Szydlo, R., Miller, M., Barker, L., Patel, N. H., Sasano, H., . . . Kenny, L. M. (2017). IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 166(2), 527-539. doi:10.1007/s10549-017-4427-xDOI: 10.1007/s10549-017-4427-x
Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer (vol 5, 30, 2015) (Journal article)
Saleem, A., Searle, G. E., Kenny, L. M., Huiban, M., Kozlowski, K., Waldman, A. D., . . . Coombes, R. C. (2017). Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer (vol 5, 30, 2015). EJNMMI RESEARCH, 7. doi:10.1186/s13550-017-0325-9DOI: 10.1186/s13550-017-0325-9
Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer (vol 5, 30, 2015) (Journal article)
Saleem, A., Searle, G. E., Kenny, L. M., Huiban, M., Kozlowski, K., Waldman, A. D., . . . Coombes, R. C. (2017). Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer (vol 5, 30, 2015). EJNMMI RESEARCH, 7. doi:10.1186/s13550-017-0323-yDOI: 10.1186/s13550-017-0323-y
Palmieri, C., Stein, R. C., Liu, X., Hudson, E., Nicholas, H., Sasano, H., . . . Coombes, R. C. (2017). IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients. BREAST CANCER RESEARCH AND TREATMENT, 165(2), 343-353. doi:10.1007/s10549-017-4328-zDOI: 10.1007/s10549-017-4328-z
Application of digital-PCR technology to determine c-MET copy number variation in paired primary breast cancer and brain metastases (Conference Paper)
Giannoudis, A., Zakaria, R., Platt-Higgins, A., Syed, K. A. R., Ashton, K., Dawson, T., . . . Palmieri, C. (2017). Application of digital-PCR technology to determine c-MET copy number variation in paired primary breast cancer and brain metastases. In CANCER RESEARCH Vol. 77. doi:10.1158/1538-7445.SABCS16-P2-03-04DOI: 10.1158/1538-7445.SABCS16-P2-03-04
First stage of an on-going phase 2, open label, international, randomized, parallel design study investigating efficacy plus safety of GTx-024 for advanced ER plus /AR plus breast cancer (BC) (Conference Paper)
Overmoyer, B., Rugo, H. S., Johnston, S., O'Shaughnessy, J. A., Palmieri, C., Schwartzberg, L. S., . . . Johnston, M. A. (2017). First stage of an on-going phase 2, open label, international, randomized, parallel design study investigating efficacy plus safety of GTx-024 for advanced ER plus /AR plus breast cancer (BC). In ANNALS OF ONCOLOGY Vol. 28. Retrieved from https://www.webofscience.com/
2016
Pushing estrogen receptor around in breast cancer (Journal article)
Lim, E., Tarulli, G., Portman, N., Hickey, T. E., Tilley, W. D., & Palmieri, C. (2016). Pushing estrogen receptor around in breast cancer. ENDOCRINE-RELATED CANCER, 23(12), T227-T241. doi:10.1530/ERC-16-0427DOI: 10.1530/ERC-16-0427
Renewed interest in the progesterone receptor in breast cancer (Journal article)
Lim, E., Palmieri, C., & Tilley, W. D. (2016). Renewed interest in the progesterone receptor in breast cancer. BRITISH JOURNAL OF CANCER, 115(8), 909-911. doi:10.1038/bjc.2016.303DOI: 10.1038/bjc.2016.303
Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer (Journal article)
Coombes, R. C., Kilburn, L. S., Tubiana-Mathieu, N., Olmos, T., Van Bochove, A., Perez-Lopez, F. R., . . . Bliss, J. M. (2016). Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer. EUROPEAN JOURNAL OF CANCER, 60, 146-153. doi:10.1016/j.ejca.2016.03.001DOI: 10.1016/j.ejca.2016.03.001
A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patients (IRIS) - Trial Results. (Conference Paper)
Palmieri, C., Stein, R. C., Liu, X., Hudson, E., Reed, S., Nicholas, H., . . . Coombes, C. (2016). A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patients (IRIS) - Trial Results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/JCO.2016.34.15_suppl.549DOI: 10.1200/JCO.2016.34.15_suppl.549
The effects of the first in class steroid sulfatase inhibitor Irosustat on FLT uptake and Ki67 in estrogen receptor positive early breast cancer: Results of the perioperative IPET study. (Conference Paper)
Palmieri, C., Szydlo, R., Miller, M., Woodley-Barker, L., Patel, N., Berwick, T., . . . Kenny, L. M. (2016). The effects of the first in class steroid sulfatase inhibitor Irosustat on FLT uptake and Ki67 in estrogen receptor positive early breast cancer: Results of the perioperative IPET study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/JCO.2016.34.15_suppl.e23140DOI: 10.1200/JCO.2016.34.15_suppl.e23140
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer (Journal article)
Palmieri, C., Macpherson, I. R. J., Yan, K., Ades, F., Riddle, P., Ahmed, R., . . . Howell, S. J. (2016). Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. ONCOTARGET, 7(11), 13209-13220. doi:10.18632/oncotarget.4801DOI: 10.18632/oncotarget.4801
A phase 2 open label, multi-center, multinational study investigating the efficacy and safety of GTx-024 on advanced, androgen receptor-positive triple negative breast cancer (AR plus TNBC) (Conference Paper)
Rugo, H., Overmoyer, B., Schwartzberg, L., Palmieri, C., Taylor, R., Hancock, M., . . . Johnston, M. A. (2016). A phase 2 open label, multi-center, multinational study investigating the efficacy and safety of GTx-024 on advanced, androgen receptor-positive triple negative breast cancer (AR plus TNBC). In CANCER RESEARCH Vol. 76. doi:10.1158/1538-7445.SABCS15-OT2-01-07DOI: 10.1158/1538-7445.SABCS15-OT2-01-07
A study of c-Jun N -terminal kinase (JNK) and c-Jun as biomarkers in early breast cancer (Conference Paper)
Palmieri, C., Rudraraju, B., Giannoudis, A., Moore, D., Shaw, J., Chan, S., . . . Abdel-Fatah, T. M. A. (2016). A study of c-Jun N -terminal kinase (JNK) and c-Jun as biomarkers in early breast cancer. In CANCER RESEARCH Vol. 76. doi:10.1158/1538-7445.SABCS15-P5-08-17DOI: 10.1158/1538-7445.SABCS15-P5-08-17
Knowledge of oncotype Dx recurrence score increases confidence and concordance in adjuvant decisions of UK oncologists (Conference Paper)
Kiernan, T., Olsson-Brown, A. C., Innes, H., Holcombe, C., Thorp, N., O'Hagan, J., . . . O'Reilly, S. (2016). Knowledge of oncotype Dx recurrence score increases confidence and concordance in adjuvant decisions of UK oncologists. In CANCER RESEARCH Vol. 76. doi:10.1158/1538-7445.SABCS15-P5-15-07DOI: 10.1158/1538-7445.SABCS15-P5-15-07
Phase 2 open label, multinational, randomized, parallel design study investigating the efficacy and safety of GTx-024 on metastatic (MET) or locally advanced (LA) ER plus /AR plus breast cancer (BC) in postmenopausal (PM) women (Conference Paper)
Overmoyer, B., Rugo, H., Schwartzberg, L., Palmieri, C., Taylor, R., Hancock, M., . . . Johnston, M. A. (2016). Phase 2 open label, multinational, randomized, parallel design study investigating the efficacy and safety of GTx-024 on metastatic (MET) or locally advanced (LA) ER plus /AR plus breast cancer (BC) in postmenopausal (PM) women. In CANCER RESEARCH Vol. 76. doi:10.1158/1538-7445.SABCS15-OT2-01-06DOI: 10.1158/1538-7445.SABCS15-OT2-01-06
SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer (Journal article)
Zwart, W., Flach, K. D., Rudraraju, B., Abdel-Fatah, T. M. A., Gojis, O., Canisius, S., . . . Palmieri, C. (2016). SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer. Clinical Cancer Research, 22(2), 479-491. doi:10.1158/1078-0432.CCR-14-3277DOI: 10.1158/1078-0432.CCR-14-3277
2015
A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition (Journal article)
Zucchini, G., Armstrong, A. C., Wardley, A. M., Wilson, G., Misra, V., Seif, M., . . . Howell, S. J. (2015). A phase II trial of low-dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition. EUROPEAN JOURNAL OF CANCER, 51(18), 2725-2731. doi:10.1016/j.ejca.2015.08.028DOI: 10.1016/j.ejca.2015.08.028
Prognostic and predictive value of ER beta 1 and ER beta 2 in the Intergroup Exemestane Study (IES)-first results from PathIES(aEuro) (Journal article)
Speirs, V., Viale, G., Mousa, K., Palmieri, C., Reed, S. N., Nicholas, H., . . . Coombes, R. C. (2015). Prognostic and predictive value of ER beta 1 and ER beta 2 in the Intergroup Exemestane Study (IES)-first results from PathIES(aEuro). ANNALS OF ONCOLOGY, 26(9), 1890-1897. doi:10.1093/annonc/mdv242DOI: 10.1093/annonc/mdv242
The Minimum Competences in Non-surgical Oncology that Medical Students Need to Acquire in Order to be Safe Foundation Year 1 (F1) Doctors: A Delphi Survey (Journal article)
Benstead, K., Palmieri, C., Brewster, A., Gilson, D., Jenkins, P., & Booth, J. (2015). The Minimum Competences in Non-surgical Oncology that Medical Students Need to Acquire in Order to be Safe Foundation Year 1 (F1) Doctors: A Delphi Survey. CLINICAL ONCOLOGY, 27(7), 373-379. doi:10.1016/j.clon.2015.03.007DOI: 10.1016/j.clon.2015.03.007
Palmieri, C. (2015). Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.. Lancet Oncol..
Effects on outcome of concomitant neoadjuvant chemotherapy-trastuzumab compared with sequential neoadjuvant chemotherapy followed by post-operative trastuzumab (Conference Paper)
Palmieri, C., Macpherson, I. R. J., Yan, K., Moraes, F. A., Riddle, P., Ahmed, R., . . . Howell, S. J. (2015). Effects on outcome of concomitant neoadjuvant chemotherapy-trastuzumab compared with sequential neoadjuvant chemotherapy followed by post-operative trastuzumab. In CANCER RESEARCH Vol. 75. Retrieved from https://www.webofscience.com/
Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer (Journal article)
Saleem, A., Searle, G. E., Kenny, L. M., Huiban, M., Kozlowski, K., Waldman, A. D., . . . Coombes, R. C. (2015). Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer. EJNMMI RESEARCH, 5. doi:10.1186/s13550-015-0103-5DOI: 10.1186/s13550-015-0103-5
Tumour volume analysis (TVA) as applied to a pilot randomized study of neoadjuvant endocrine versus neoadjuvant chemotherapy (NEOCENT). (Conference Paper)
Gordon, A., Palmieri, C., Cleator, S. J., Morden, J. P., & Coombes, R. C. (2015). Tumour volume analysis (TVA) as applied to a pilot randomized study of neoadjuvant endocrine versus neoadjuvant chemotherapy (NEOCENT).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33. Retrieved from https://www.webofscience.com/
2014
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer (Journal article)
Palmieri, C., Cleator, S., Kilburn, L. S., Kim, S. B., Ahn, S. -H., Beresford, M., . . . Coombes, R. C. (2014). NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 148(3), 581-590. doi:10.1007/s10549-014-3183-4DOI: 10.1007/s10549-014-3183-4
Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer (Journal article)
Rudraraju, B., Droog, M., Abdel-Fatah, T. M. A., Zwart, W., Giannoudis, A., Malki, M. I., . . . Palmieri, C. (2014). Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 147(2), 295-309. doi:10.1007/s10549-014-3098-0DOI: 10.1007/s10549-014-3098-0
Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer (Journal article)
Elliott, K. M., Dent, J., Stanczyk, F. Z., Woodley, L., Coombes, R. C., Purohit, A., & Palmieri, C. (2014). Effects of aromatase inhibitors and body mass index on steroid hormone levels in women with early and advanced breast cancer. BRITISH JOURNAL OF SURGERY, 101(8), 939-948. doi:10.1002/bjs.9477DOI: 10.1002/bjs.9477
Multicenter Experience of Nonpegylated Liposomal Doxorubicin Use in the Management of Metastatic Breast Cancer (Journal article)
Palmieri, C., Misra, V., Januszewski, A., Yosef, H., Ashford, R., Keary, I., & Davidson, N. (2014). Multicenter Experience of Nonpegylated Liposomal Doxorubicin Use in the Management of Metastatic Breast Cancer. Clinical Breast Cancer, 14(2), 85-93. doi:10.1016/j.clbc.2013.10.011DOI: 10.1016/j.clbc.2013.10.011
Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund (Journal article)
Ramaswami, R., O'Cathail, S. M., Brindley, J. H., Silcocks, P., Mahmoud, S., & Palmieri, C. (2014). Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund. FUTURE ONCOLOGY, 10(3), 363-376. doi:10.2217/FON.13.210DOI: 10.2217/FON.13.210
Prior exposure to chemotherapy: a marker of sensitivity and selection for antiangiogenic therapy in breast cancer? (Journal article)
Xynos, I. D., Tanna, N., Patten, D. K., & Palmieri, C. (2014). Prior exposure to chemotherapy: a marker of sensitivity and selection for antiangiogenic therapy in breast cancer?. EXPERT REVIEW OF ANTICANCER THERAPY, 14(2), 163-172. doi:10.1586/14737140.2014.846220DOI: 10.1586/14737140.2014.846220
Breast cancer: Current and future endocrine therapies (Journal article)
Palmieri, C., Patten, D. K., Januszewski, A., Zucchini, G., & Howell, S. J. (2014). Breast cancer: Current and future endocrine therapies. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 382(1), 695-723. doi:10.1016/j.mce.2013.08.001DOI: 10.1016/j.mce.2013.08.001
2013
Eccles, S. A., Aboagye, E. O., Ali, S., Anderson, A. S., Armes, J., Berditchevski, F., . . . Thompson, A. M. (2013). Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. . Breast cancer research : BCR, 15(5), R92. doi:10.1186/bcr3493DOI: 10.1186/bcr3493
ABC of Cancer Care (Book)
Palmieri, C., Bird, E., & Simcock, R. (Eds.) (2013). ABC of Cancer Care. Chichester, West Sussex: Wiley-Blackwell.
An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study) (Journal article)
Coombes, R. C., Tat, T., Miller, M. L., Reise, J. A., Mansi, J. L., Hadjiminas, D. J., . . . Stebbing, J. (2013). An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study). Ann Oncol, 24, 924-930.
ChIPing away at breast cancer. (Journal article)
Magnani, L., Carrol, J., Zwart, W., & Palmieri, C. (2013). ChIPing away at breast cancer.. Lancet Oncol, 13, 1185-1187.
Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer (Journal article)
Palmieri, C., Caley, M. P., Purshouse, K., Fonseca, A. V., Rodriguez-Teja, M., Kogianni, G., . . . Sturge, J. (2013). Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer. Br J Cancer, (15), 163-169.
Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer. (Journal article)
Palmieri, C., Caley, M. P., Purshouse, K., Fonseca, A. V., Rodriguez-Teja, M., Kogianni, G., . . . Sturge, J. (2013). Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer.. Br J Cancer., 108(1), 163-169.
Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor (Journal article)
Mohammed, H., D'Santos, C., Serandour, A. A., Ali, H. R., Brown, G. D., Atkins, A., . . . Carroll, J. S. (2013). Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep, 3, 324-329.
Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance (Journal article)
Palmieri, C., Gojis, O., Rudraraju, B., Stamp-Vincent, C., Wilson, D., Langdon, S., . . . Faratian, D. (2013). Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. Br J Cancer.
Is the presence of small volume disease in the sentinel node an indication for axillary clearance? (Journal article)
Patten, D. K., Leff, D. R., Wani, Z., Cleator, S. J., Palmieri, C., Coombes, R. C., & Hadjiminas, D. J. (2013). Is the presence of small volume disease in the sentinel node an indication for axillary clearance?. Breast., 22, 70-73.
Patient attitudes towards undergoing additional breast biopsy for research (Journal article)
Naim, F., Ballinger, R., Rombach, I., Hadjiminas, D. J., Al-Mufti, R., Hogben, R. K., . . . Cleator, S. J. (2013). Patient attitudes towards undergoing additional breast biopsy for research. Breast..
2012
A Randomised Feasibility Study of Docetaxel Versus Vinorelbine in Advanced Breast Cancer (Journal article)
Palmieri, C., Alifrangis, C., Shipway, D., Tat, T., Watson, V., Mackie, D., . . . Coombes, R. C. (2012). A Randomised Feasibility Study of Docetaxel Versus Vinorelbine in Advanced Breast Cancer. The Oncologist, 17(11)(11), 1429-e47.
A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer (Journal article)
Palmieri, C., Alifrangis, C., Shipway, D., Tat, T., Watson, V., Mackie, D., . . . Coombes, R. C. (2012). A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer. Oncologist, 17, 1429-e47..
A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer (Journal article)
Palmieri, C., Alifrangis, C., Shipway, D., Tat, T., Watson, V., Mackie, D., . . . Coombes, R. C. (2012). A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer. Oncologist, 17, 1429-e47..
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer (Journal article)
Ross-Innes, C. S., Stark, R., Teschendorff, A. E., Holmes, K. A., Ali, H. R., Dunning, M. J., . . . Carroll, J. S. (2012). Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature, 481, 389-393.
Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. (Journal article)
Shaw, J. A., Page, K., Blighe, K., Hava, N., Guttery, D., Ward, B., . . . Coombes, R. C. (2012). Genomic analysis of circulating cell-free DNA infers breast cancer dormancy.. Genome Res, 22, 220-231.
High frequency of complex TP53 mutations in CNS metastases from breast cancer (Journal article)
Lo Nigro, C., Vivenza, D., Monteverde, M., Lattanzio, L., Gojis, O., Garrone, O., . . . Crook, T. (2012). High frequency of complex TP53 mutations in CNS metastases from breast cancer. Br J Cancer, 106, 397-404.
Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy (Journal article)
Contractor, K., Challapalli, A., Tomasi, G., Rosso, L., Wasan, H., Stebbing, J., . . . Aboagye, E. (2012). Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy. Phys Med Biol, 57, 3419-3433.
Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas (Journal article)
Palmieri, C., Rudraraju, B., Monteverde, M., Lattanzio, L., Gojis, O., Brizio, R., . . . Crook, T. (2012). Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas. Br J Cancer., 107, 375-381.
Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas. (Journal article)
Palmieri, C., Rudraraju, B., Monteverde, M., Lattanzio, L., Gojis, O., Brizio, R., . . . Crook, T. (2012). Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas.. Br J Cancer., 107(2), 375-381.
NT5E CpG island methylation is a favourable breast cancer biomarker (Journal article)
Lo Nigro, C., Monteverde, M., Lee, S., Lattanzio, L., Vivenza, D., Comino, A., . . . Crook, T. (2012). NT5E CpG island methylation is a favourable breast cancer biomarker. Br J Cancer, 26, 75-83.
Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries (Journal article)
Saini, K. S., Taylor, C., Ramirez, A. J., Palmieri, C., Gunnarsson, U., Schmoll, H. J., . . . de Azambuja, E. (2012). Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. Ann Oncol, 23, 853-859.
Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse (Journal article)
Palmieri, C., Monteverde, M., Lattanzio, L., Gojis, O., Rudraraju, B., Fortunato, M., . . . Crook, T. (2012). Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse. Br J Cancer, 107, 732-738.
Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse. (Journal article)
Palmieri, C., Monteverde, M., Lattanzio, L., Gojis, O., Rudraraju, B., Fortunato, M., . . . Crook, T. (2012). Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse.. Brit J Cancer, 107(4), 732-738.
TGFβ(1)-Endo180-dependent collagen deposition is dysregulated at the tumour-stromal interface in bone metastasis (Journal article)
Caley, M. P., Kogianni, G., Adamarek, A., Gronau, J. H., Rodriguez-Teja, M., Fonseca, A. V., . . . Sturge, J. (2012). TGFβ(1)-Endo180-dependent collagen deposition is dysregulated at the tumour-stromal interface in bone metastasis. J Pathol, 226, 775-783.
The 2011 EBCTCG polychemotherapy overview (Journal article)
Palmieri, C., & Jones, A. (2012). The 2011 EBCTCG polychemotherapy overview. Lancet, 379, 390-392.
2011
. Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era (Journal article)
Krell, J., James, C. R., Shah, D., Gojis, O., Lim, A., Riddle, P., . . . Palmieri, C. (2011). . Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era. Clin Breast Cancer, 11, 93-102.
Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography (Journal article)
Contractor, K. B., Kenny, L. M., Stebbing, J., Challapalli, A., Al-Nahhas, A., Palmieri, C., . . . Aboagye, E. O. (2011). Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography. Nucl Med Commun, 32, 997-1004.
Effect of Tamoxifen or Anastrozole on steroid sulphatase activity and serum androgen concentrations in postmenopausal women with breast cancer (Journal article)
Stanway, S. J., Palmieri, C., Stanczyk, F. Z., Folkerd, E. J., Dowsett, M., Ward, R., . . . Purohit, A. (2011). Effect of Tamoxifen or Anastrozole on steroid sulphatase activity and serum androgen concentrations in postmenopausal women with breast cancer. Anticancer Res., 31, 1367-1372.
Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era (Journal article)
Palmieri, C., Shah, D., Krell, J., Gojis, O., Hogben, K., Riddle, P., . . . Cleator, S. (2011). Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era. Clin Breast Cancer, 11, 93-102.
Role of fulvestrant in the management of postmenopausal breast cancer (Journal article)
Krell, J., Januszewski, A., Yan, K., & Palmieri, C. (2011). Role of fulvestrant in the management of postmenopausal breast cancer. Expert Rev Anticancer Ther., 11, 1641-1645.
2010
A review of rechallenging with anthracycline and taxane in the treatment of metastatic breast cancer (Journal article)
Palmieri, C., Krell, J., James, C. R., Harper-Wynne, C., Misra, V., Cleator, S., & Miles, D. (2010). A review of rechallenging with anthracycline and taxane in the treatment of metastatic breast cancer. Nat Rev Clin Oncol. 2010;7:, 7, 561-574.
Reproducibility of [11C]Choline Positron Emission Tomography and Effect of Trastuzumab. (Journal article)
Kenny, L. M., Contractor, K. B., Hinz, R., Stebbing, J., Palmieri, C., Jiang, J., . . . Aboagye, E. O. (2010). Reproducibility of [11C]Choline Positron Emission Tomography and Effect of Trastuzumab.. Clin Cancer Res, 16, 4236-4245.
The role of SRC-3 in human breast cancer (Journal article)
Gojis, O., Rudraraju, B., Gudi, M., Hogben, K., Sousha, S., Coombes, R. C., . . . Palmieri, C. (2010). The role of SRC-3 in human breast cancer. Nat Rev Clin Oncol., 7, 83-89.
The role of steroid receptor coactivator-3 (SRC-3) in human malignant disease. (Journal article)
Gojis, O., Rudraraju, B., Alifrangis, C., Krell, J., Libalova, P., & Palmieri, C. (2010). The role of steroid receptor coactivator-3 (SRC-3) in human malignant disease.. Eur J Surg Oncol, 36, 224-229.
Why biopsying metastatic breast cancer should be routine (Journal article)
Sharma, A., Crook, T., Thompson, A., & Palmieri, C. (2010). Why biopsying metastatic breast cancer should be routine. Nat Rev Clin Oncol., 7, 72-74.
2009
A 2009 Update on the Treatment of Patients with Hormone Receptor-Positive Breast Cancer (Journal article)
Cleator, S. J., Ahamed, E., Coombes, R. C., & Palmieri, C. (2009). A 2009 Update on the Treatment of Patients with Hormone Receptor-Positive Breast Cancer. Clin Breast Cancer, Suppl, S6-S17.
Altered Tissue 3'-Deoxy-3'-[18F]Fluorothymidine Pharmacokinetics in Human Breast Cancer Following Capecitabine Treatment Detected by Positron Emission Tomography (Journal article)
Kenny, L. M., Contractor, K. B., Stebbing, J., Al-Nahhas, A., Palmieri, C., Shousha, S., . . . Aboagye, E. O. (2009). Altered Tissue 3'-Deoxy-3'-[18F]Fluorothymidine Pharmacokinetics in Human Breast Cancer Following Capecitabine Treatment Detected by Positron Emission Tomography. Clin Cancer Res, 15, 6649-6657.
Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. (Journal article)
Slade, M. J., Payne, R., Riethdorf, S., Ward, B., Zaidi, S. A., Stebbing, J., . . . Coombes, R. C. (2009). Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment.. Br J Cancer, 100, 160-166.
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. (Journal article)
Barrett-Lee, P. J., Dixon, J. M., Farrell, C., Jones, A., Leonard, R., Murray, N., . . . Verrill, M. W. (2009). Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.. Ann Oncol, 20, 816-827.
Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition:a single centre experience. (Journal article)
Wang, J., Jain, S., Coombes, C. R., & Palmieri, C. (2009). Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition:a single centre experience.. Breast Journal, 15, 247-253.
R.E. Francis , S.S. Myatt, J .Krol, J. Hartman, B. Peck, U.B. McGovern, J. Wang, S.K. Guest, A. Filipovic, O. Gojis, C. Palmieri, D. Peston, S. Shousha, Q. Yu, P. Sicinski, R.C. Coombes, E.W. Lam . FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer (Journal article)
Francis, R. E., Myatt, S. S., Krol, J., Hartman, J., Peck, B., McGovern, U. B., . . . Lam, E. W. (2009). R.E. Francis , S.S. Myatt, J .Krol, J. Hartman, B. Peck, U.B. McGovern, J. Wang, S.K. Guest, A. Filipovic, O. Gojis, C. Palmieri, D. Peston, S. Shousha, Q. Yu, P. Sicinski, R.C. Coombes, E.W. Lam . FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol., 35, 57-68.
[11C]choline Positron Emission Tomography (PET) in Breast Cancer. (Journal article)
positron emission tomography in estrogen receptor-positive breas, C. C. (2009). [11C]choline Positron Emission Tomography (PET) in Breast Cancer.. Clin Cancer Res., 15, 5503-5510.
2008
Adjuvant radiotherapy for breast cancer (Journal article)
Hiley, C., Tutt, A., Torres, M., & Palmieri, C. (2008). Adjuvant radiotherapy for breast cancer. BMJ, 337, a2843.
Adjuvant radiotherapy for breast cancer. (Journal article)
Hiley, C., Tutt, A., Torres, M., & Palmieri, C. (2008). Adjuvant radiotherapy for breast cancer.. BMJ, 337, a2843.
Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer. (Journal article)
Stavridi, F., & Palmieri, C. (2008). Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer.. Expert Rev Anticancer Ther, 8, 1859-1869.
Ethnicity and breast cancer research (Journal article)
Palmieri, C., Coombes, R. C., Kim, S. B., & Cleator, S. (2008). Ethnicity and breast cancer research. Lancet. 2008;372:188-9, 372, 188-189.
Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients (Journal article)
Kenny, L. M., Coombes, R. C., Oulie, I., Contractor, K. B., Miller, M., Spinks, T. J., . . . Aboagye, E. O. (2008). Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med, 49, 879-886.
R.Thomas & C.Palmieri. Angiosarcoma of the breast following breast preserving surgery and radiotherapy: a review of the literature. (Journal article)
Thomas, R., & Palmieri, C. (2008). R.Thomas & C.Palmieri. Angiosarcoma of the breast following breast preserving surgery and radiotherapy: a review of the literature.. Nat Clin Pract Oncol., (5), 727-736.
2007
C.Palmieri, T.Dhillon, R.A.Fisher, A.M.Young, D.Short, H.Mitchell, P.Savage, E.S. Newlands, B.W. Hancock , M.J.Seckl. Management and outcome of healthy women with a persistently elevated β-hCG (Journal article)
Palmieri, C., Dhillon, T., Fisher, R. A., Young, A. M., Short, D., Mitchell, H., . . . Seckl, M. J. (2007). C.Palmieri, T.Dhillon, R.A.Fisher, A.M.Young, D.Short, H.Mitchell, P.Savage, E.S. Newlands, B.W. Hancock , M.J.Seckl. Management and outcome of healthy women with a persistently elevated β-hCG. Gynecol Oncol, 106, 35-43.
Neo-adjuvant 5-Fluorouracil, Epirubicin and cyclophosphamide (FEC) chemotherapy followed by docetaxel in refractory patents with locally advanced breast cancer (Journal article)
Heller, W., Mazhar, D., Ward, R., Sinnett, H. D., Lowdell, C., Phillips, R., . . . Coombes, R. C. (2007). Neo-adjuvant 5-Fluorouracil, Epirubicin and cyclophosphamide (FEC) chemotherapy followed by docetaxel in refractory patents with locally advanced breast cancer. Oncol Rep, 17, 253-259.
2006
AIDS associated malignancies. (Journal article)
Bower, M., Palmieri, C., & Stebbing, J. (2006). AIDS associated malignancies.. Update on Cancer Therapeutics, 1, 221-234.
AIDS related malignancies: changing epidemiology and impact of HAART. (Journal article)
Bower, M., Palmieri, C., & Dhillon, T. (2006). AIDS related malignancies: changing epidemiology and impact of HAART.. Current Opin Inf Dis, 19, 14-19.
AIDS related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy (Journal article)
Palmieri, C., Treibel, T., Large, O. M., & Bower, M. (2006). AIDS related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy. QJM., 99, 811-826.
Pulmonary AIDS related Kaposi Sarcoma in era of HAART. (Journal article)
Palmieri, C., Dhillon, T., Thirlwell, C., Newsom-Davis, T., Young, A. M., Nelson, M., . . . Bower, M. (2006). Pulmonary AIDS related Kaposi Sarcoma in era of HAART.. HIV Medicine, 7, 291-293.
Serum 25-hydroxyvitamin D levels in early and advanced breast cancer (Journal article)
Palmieri, C., MacGregor, T., Girgis, S., & Vigushin, D. M. (2006). Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. J Clin Pathol, 59, 1334-1336.
The presentation and survival of patients with non-cutanous AIDS-associated Kaposi's sarcoma. (Journal article)
Stebbing, J., Mazhar, D., Lewis, R., Palmieri, C., Hatzimichael, E., Nelson, M., . . . Bower, M. (2006). The presentation and survival of patients with non-cutanous AIDS-associated Kaposi's sarcoma.. Ann Oncol, 17, 503-506.
Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia (Journal article)
Dhillon, T., Palmieri, C., Sebire, N. J., Lindsay, I., Newlands, E. S., Schmid, P., . . . Seckl, M. J. (2006). Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia. J Reprod Med, 51, 879-887.
2005
Targeted histone deacetylase inhibition for cancer prevention and therapy (Journal article)
Palmieri, C., Coombes, R. C., & Vigushin, D. M. (2005). Targeted histone deacetylase inhibition for cancer prevention and therapy. Prog Drug Res, 63, 147-181.
Therapeutic monoclonal antibodies in oncology. (Journal article)
Levene, A. P., Singh, G., & Palmieri, C. (2005). Therapeutic monoclonal antibodies in oncology.. J R Soc Med, 98, 146-152.
Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis (Journal article)
Fraser, S. P., Diss, J. K., Chioni, A. M., Mycielska, M. E., Pan, H., Yamaci, R. F., . . . Djamgoz, M. B. (2005). Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Research ., 15, 5381-5389.
2004
Expression of oestrogen receptor (ER)-beta and its variants, but not ER alpha, in purified adult human mammary fibroblasts. (Journal article)
Palmieri, C., Saji, S., Sakaguchi, H., Cheng, G., Sunters, A., O'Hare, M. J., . . . Lam, E. W. (2004). Expression of oestrogen receptor (ER)-beta and its variants, but not ER alpha, in purified adult human mammary fibroblasts.. J Mol Endocrinol, 33, 35-50.
Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomised, placebo-controlled trial. (Journal article)
Neary, N. M., Small, C. J., Wren, A. M., Lee, J. L., Druce, M. R., Palmieri, C., . . . Bloom, S. R. (2004). Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomised, placebo-controlled trial.. J. Clin Endocrinol Metab, 89, 2832-2836.
The expression of ERbetacx in human breast cancer and the relationship to endocrine therapy and survival. (Journal article)
Palmieri, C., Lam, E. W., Mansi, J., MacDonald, C., Shousha, S., Madden, P., . . . Coombes, R. C. (2004). The expression of ERbetacx in human breast cancer and the relationship to endocrine therapy and survival.. Clin Cancer Res, 10, 2421-2428.
2003
Fibroblast growth factor 7, secreted by breast fibroblasts, is an interleukin-1beta-induced paracrine growth factor for human breast cancer cells. (Journal article)
Palmieri, C., Roberts-Clark, D., Assadi-Sabet, A., Coope, R. C., O'Hare, M., Sunters, A., . . . Coombes, R. C. (2003). Fibroblast growth factor 7, secreted by breast fibroblasts, is an interleukin-1beta-induced paracrine growth factor for human breast cancer cells.. J Endocrinol, 177, 65-81.
2002
Estrogen receptor beta in breast cancer. (Journal article)
Palmieri, C., Cheng, G. J., Saji, S., Zelada-Hedman, M., Wärri, A., Weihua, Z., . . . Gustafsson, J. A. (2002). Estrogen receptor beta in breast cancer.. Endocr Relat Cancer, 9, 1-13.
2001
Estrogen receptors and proliferation markers in primary and recurrent breast cancer. (Journal article)
Jensen, E. V., Cheng, G., Palmieri, C., Saji, S., Mäkelä, S., Van Noorden, S., . . . Gustafsson, J. A. (2001). Estrogen receptors and proliferation markers in primary and recurrent breast cancer.. Proc Natl Acad Sci USA, 98, 15197-15202.
2000
Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer. (Journal article)
Udom, D. I., Vigushin, D. M., Linardou, H., Graham, H., Palmieri, C., & Coombes, R. C. (2000). Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer.. Eur J Cancer 2000;, 36, 177-182.
